Wenning Qin

Dr. Wenning Qin is SVP, Head of Research at eGenesis, and is responsible for the editing of the porcine genome for the purpose of developing human compatible cells, tissues, and organs to advance products for transplantation.

Dr. Qin has over 25 years of experience in gene editing and scientific leadership spanning Monsanto Life Sciences, Pharmacia Corporation, Pfizer Inc., Biogen Idec, and the Jackson Laboratory. Numerous programs Dr. Qin supported – across oncology, neuroscience, and cardiovascular disease – have advanced to IND and approval.

Dr. Qin earned a B.S. in Public Health and an M.S. in Cardiovascular Physiology from Tongji Medical University and a Ph.D. in cardiovascular pharmacology from Southern Illinois University. Dr. Qin completed postdoctoral training in transcriptional regulation of gene expression at Washington University School of Medicine.